Mechanism of Decreased Iron Absorption in Obesity: Controlling Adiposity-related Inflammation
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Zurich, Switzerland, 8092
- Human Nutrition Laboratory ETH Zurich
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- normal-weight (BMI18.5-24.9kg/m2) or obesity (BMI 29-40kg/m2)
- pre-menopausal
- no chronic illness and no significant medical conditions that could influence iron or inflammatory status other than obesity
- no-smoking
Exclusion Criteria:
- Diagnosed chronic disease or gastrointestinal disorders
- Metabolic disorders (e.g. diabetes)
- Regular use of medication (except oral contraceptives)
- Subject on a weight loss diet or planning to start a weight loss diet during the duration of the study
- Pregnancy or lactation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: BASIC_SCIENCE
- Allocation: NON_RANDOMIZED
- Interventional Model: PARALLEL
- Masking: NONE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
EXPERIMENTAL: normal-weight
normal-weight women
|
|
|
EXPERIMENTAL: obesity
obese women
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Fractional iron absorption
Time Frame: Days 15 and 45
|
The fractional iron absorption from four test meals will be calculated based on the shift of the iron isotopic ratios in the collected blood samples 14 days after administration of the isotopically labeled meals.
Calculation of fractional iron absorption will take into account the principles of isotope dilution and the fact that iron isotopic labels are not mono-isotopic.
The investigators assumed iron incorporation into erythrocytes to be constant.
Blood volume, needed for the calculation of fractional iron absorption will be estimated based on available data on blood volume estimations in obese women.
|
Days 15 and 45
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Plasma ferritin
Time Frame: Days 1, 15, 30, 45
|
Days 1, 15, 30, 45
|
|
Hemoglobin
Time Frame: Days 1, 15, 30, 45
|
Days 1, 15, 30, 45
|
|
Transferrin receptor
Time Frame: Days 1, 15, 30, 45
|
Days 1, 15, 30, 45
|
|
Hepcidin
Time Frame: Days 1, 15, 30, 45
|
Days 1, 15, 30, 45
|
|
c-reactive protein
Time Frame: Days 1, 15, 30, 45
|
Days 1, 15, 30, 45
|
|
interleukin-6
Time Frame: Days 1, 15, 30, 45
|
Days 1, 15, 30, 45
|
|
alpha-1-acid-glycoprotein
Time Frame: Days 1, 15, 30, 45
|
Days 1, 15, 30, 45
|
Collaborators and Investigators
Sponsor
Sponsor
Collaborators
Collaborators
Investigators
Investigators
- Principal Investigator: Isabelle Herter-Aeberli, PhD, University of Zurich
Study record dates
Study Major Dates
Study Start (ACTUAL)
Study Start
Primary Completion (ACTUAL)
Primary Completion
Study Completion (ACTUAL)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
First Posted
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Pathologic Processes
- Overnutrition
- Nutrition Disorders
- Overweight
- Body Weight
- Obesity
- Inflammation
- Physiological Effects of Drugs
- Molecular Mechanisms of Pharmacological Action
- Peripheral Nervous System Agents
- Enzyme Inhibitors
- Analgesics
- Sensory System Agents
- Anti-Inflammatory Agents, Non-Steroidal
- Analgesics, Non-Narcotic
- Anti-Inflammatory Agents
- Antirheumatic Agents
- Cyclooxygenase Inhibitors
- Ibuprofen
Other Study ID Numbers
Other Study ID Numbers
- Fe_Abs_Ibu
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.